ArticleJournal of tissue engineering
Exploring the memory of the extracellular matrix using MASH-derived decellularized scaffolds.
Article in Journal of tissue engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence suggests that the extracellular matrix (ECM) possesses a "memory" that can influence cell physiology and recellularization outcomes. Understanding this memory is essential to allow the use of bioengineered organs derived from diseased ECM, offering a solution to the critical organ shortage. To address this, we investigated whether the memory of ECM derived from metabolic dysfunction-associated steatohepatitis (MASH) livers impacts disease establishment following transplantation. Partial orthotopic transplantation of decellularized MASH-derived ECM was performed in control and MASH recipients. Histological analysis confirmed complete recellularization; however, molecular and metabolomic analyses revealed that MASH ECM stimulated de novo lipogenesis and fibrogenesis, inducing impaired lipid oxidation and mitochondrial dysfunction, which contributed to disease progression by promoting altered lipid turnover and inflammatory signalling. In vitro analysis revealed that MASH-ECM disrupted calcium signalling and promoted the maintenance of a pathological phenotype. Although derived from diseased livers, human ECM can promote cell survival and permissiveness. In conclusion, diseased ECM memory impacts cell physiology, suggesting that the scaffold can drive disease progression independently of the cellular environment. Thus, further studies are needed to develop strategies capable of reversing the pathological memory associated with ECM to allow its use in liver transplantation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.